Literature DB >> 18296105

Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study.

M P Weijenberg1, P W M Aardening, T M de Kok, A F P M de Goeij, P A van den Brandt.   

Abstract

Since a KRAS oncogene mutation is an early event in colorectal cancer development and cigarette smoking is thought to have an effect on early stages of colorectal tumorigenesis, smoking, especially long-term smoking, may be associated with the risk for colorectal cancer with KRAS oncogene mutations. In the Netherlands Cohort Study on diet and cancer (n=120,852 men and women), using a case-cohort design, adjusted incidence rate ratios (RR) and 95% confidence intervals (CI) were computed for colorectal tumors with wild-type and with mutated KRAS gene, and with specific G:C-->T:A or G:C-->A:T point mutations in KRAS, according to cigarette smoking status, frequency, duration, pack years, age at first exposure, years since cessation, inhalation and filter usage. After 7.3 years and excluding the first 2.3 years, 648 cases and 4083 sub-cohort members were included in the analyses. Ex-smokers, but not current smokers, were at increased risk for colorectal cancer with wild-type KRAS gene tumors when compared with never smokers, albeit not statistically significant (RR 1.26, 95% CI 0.96-1.66). This was not observed for KRAS mutated tumors when comparing ex-smokers with never smokers (RR 1.15, 95% CI 0.79-1.66). The highest category of smoking frequency (>20 cigarettes/day) and inhalation of smoke were associated with an increased risk for colorectal cancer with wild-type KRAS gene tumors, though not statistically significant, when compared with never smoking (frequency: RR 1.24, 95% CI 0.90-1.71 and inhalation: RR 1.25, 95% CI 0.94-1.67). These associations were strongest in men (ex-smokers: RR 1.79, 95% CI 1.00-3.20; frequency: RR 1.91, 95% CI 1.03-3.52; inhalation: RR 1.69, 95% CI 0.94-3.04). No associations were observed between any of the smoking characteristics and the risk for colorectal cancer with mutated KRAS gene tumors, nor where there any clear associations with tumors with specific G:C-->A:T transitions or G:C-->T:A transversions. These results suggest that, in contrast to the hypothesis, smoking does not increase the risk for colorectal tumors with a mutated KRAS gene. Some smoking characteristics, i.e. being an ex-smoker, frequency and inhalation, may be associated with risk for colorectal cancer characterized by the wild-type KRAS gene, especially in men.

Entities:  

Mesh:

Year:  2008        PMID: 18296105     DOI: 10.1016/j.mrgentox.2007.12.008

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  19 in total

Review 1.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

2.  Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis.

Authors:  Ke Chen; Guanggai Xia; Changhua Zhang; Yunwei Sun
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression.

Authors:  Paul Lochhead; Andrew T Chan; Reiko Nishihara; Charles S Fuchs; Andrew H Beck; Edward Giovannucci; Shuji Ogino
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

4.  Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women.

Authors:  N J Samadder; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Charles F Lynch; Kristin E Anderson; Amy J French; Robert W Haile; Lisa J Harnack; John D Potter; Susan L Slager; Thomas C Smyrk; Stephen N Thibodeau; James R Cerhan; Paul J Limburg
Journal:  Am J Gastroenterol       Date:  2012-02-21       Impact factor: 10.864

5.  APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study.

Authors:  Fernando Martínez; Carlos Fernández-Martos; María Jesús Quintana; Antoni Castells; Antonio Llombart; Francisco Ińiguez; Vicente Guillem; Francisco Dasí
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

6.  Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

Authors:  Wilson I Gonsalves; Michelle R Mahoney; Daniel J Sargent; Garth D Nelson; Steven R Alberts; Frank A Sinicrope; Richard M Goldberg; Paul J Limburg; Stephen N Thibodeau; Axel Grothey; Joleen M Hubbard; Emily Chan; Suresh Nair; Jeffrey L Berenberg; Robert R McWilliams
Journal:  J Natl Cancer Inst       Date:  2014-06-12       Impact factor: 13.506

7.  Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.

Authors:  Amanda I Phipps; Qian Shi; Polly A Newcomb; Garth D Nelson; Daniel J Sargent; Steven R Alberts; Paul J Limburg
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

8.  Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population.

Authors:  Jyh-Ming Liou; Ming-Shiang Wu; Chia-Tung Shun; Han-Mo Chiu; Mei-Jyh Chen; Chien-Chuan Chen; Hsiu-Po Wang; Jaw-Town Lin; Jin-Tung Liang
Journal:  Int J Colorectal Dis       Date:  2011-05-07       Impact factor: 2.571

9.  Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.

Authors:  Nadine Jackson McCleary; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al Benson; Richard Goldberg; Jeffrey A Meyerhardt
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

10.  Somatic alterations, metabolizing genes and smoking in rectal cancer.

Authors:  Karen Curtin; Wade S Samowitz; Roger K Wolff; Jennifer Herrick; Bette J Caan; Martha L Slattery
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.